Fractyl Health Inc (GUTS)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.08-4.42%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Fractyl Health Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-1.155
Annual ending 2026-12-31
Revenue	—	12.43M
EPS	—	-4.056
Annual ending 2027-12-31
Revenue	—	15.32M
EPS	—	-5.686

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash runway into early 2027	Fractyl Health aims to maintain cash through early 2027, securing operations.	Intact	cash runway falls short of early 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve clinical milestones for Revita and Rejuva	It targets key clinical milestones for its Revita and Rejuva therapies.	Improving	failure to meet key clinical milestones in 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Address Nasdaq listing compliance	A supporting condition in Fractyl Health Inc's published investment case. The stated target is Resolve Nasdaq compliance issues to maintain listing.	Under Pressure	failure to resolve Nasdaq compliance leading to delisting	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

Unavailable → Unavailable · observed estimates

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	4 / 3
2026-07-25	Unavailable	Unavailable	4 / 3
2026-07-26	Unavailable	Unavailable	4 / 3
2026-07-27	Unavailable	Unavailable	4 / 3
2026-07-28	$-0.48	Unavailable	6 / 4
2026-07-29	$-0.50	Unavailable	6 / 4
2026-07-30	$-0.50	Unavailable	6 / 4
2026-07-31	$-0.50	Unavailable	6 / 4
2026-08-01	Unavailable	Unavailable	4 / 3
2026-08-02	$-0.50	Unavailable	6 / 4
2026-08-03	Unavailable	Unavailable	4 / 3
2026-08-04	$-0.50	Unavailable	6 / 4
2026-08-05	$-0.50	Unavailable	6 / 4
2026-08-06	$-0.50	Unavailable	6 / 4
2026-08-07	Unavailable	Unavailable	4 / 3
2026-08-08	$-0.50	Unavailable	6 / 4
2026-08-09	$-0.50	Unavailable	6 / 4
2026-08-10	$-0.50	Unavailable	6 / 4
2026-08-12	Unavailable	Unavailable	4 / 3
2026-08-13	$-0.49	Unavailable	6 / 4
2026-08-14	Unavailable	Unavailable	4 / 3
2026-08-15	Unavailable	Unavailable	4 / 3
2026-08-16	Unavailable	Unavailable	4 / 3
2026-08-17	Unavailable	Unavailable	4 / 3
2026-08-18	Unavailable	Unavailable	4 / 3
2026-08-19	Unavailable	Unavailable	4 / 3
2026-08-20	Unavailable	Unavailable	4 / 3
2026-08-21	Unavailable	Unavailable	4 / 3
2026-08-22	Unavailable	Unavailable	4 / 3
2026-08-23	Unavailable	Unavailable	4 / 3
2026-08-24	Unavailable	Unavailable	4 / 3
2026-08-25	Unavailable	Unavailable	4 / 3
2026-08-26	Unavailable	Unavailable	4 / 3
2026-08-27	Unavailable	Unavailable	4 / 3
2026-08-28	Unavailable	Unavailable	4 / 3
2026-08-29	Unavailable	Unavailable	4 / 3
2026-08-30	Unavailable	Unavailable	4 / 3
2026-08-31	Unavailable	Unavailable	4 / 3
2026-09-01	Unavailable	Unavailable	4 / 3
2026-09-02	Unavailable	Unavailable	4 / 3
2026-09-03	Unavailable	Unavailable	4 / 3
2026-09-04	Unavailable	Unavailable	4 / 3
2026-09-05	Unavailable	Unavailable	4 / 3
2026-09-06	Unavailable	Unavailable	4 / 3
2026-09-07	Unavailable	Unavailable	4 / 3
2026-09-08	Unavailable	Unavailable	4 / 3
2026-09-09	Unavailable	Unavailable	4 / 3
2026-09-10	Unavailable	Unavailable	4 / 3
2026-09-11	Unavailable	Unavailable	4 / 3
2026-09-12	Unavailable	Unavailable	4 / 3
2026-09-13	Unavailable	Unavailable	4 / 3
2026-09-14	Unavailable	Unavailable	4 / 3
2026-09-15	Unavailable	Unavailable	4 / 3
2026-09-16	Unavailable	Unavailable	4 / 3
2026-09-17	Unavailable	Unavailable	4 / 3
2026-09-18	Unavailable	Unavailable	4 / 3
2026-09-19	Unavailable	Unavailable	4 / 3
2026-09-20	Unavailable	Unavailable	4 / 3
2026-09-21	Unavailable	Unavailable	4 / 3
2026-09-22	Unavailable	Unavailable	4 / 3
2026-09-23	Unavailable	Unavailable	4 / 3
2026-09-24	Unavailable	Unavailable	4 / 3
2026-09-25	Unavailable	Unavailable	4 / 3
2026-09-26	Unavailable	Unavailable	4 / 3
2026-09-27	Unavailable	Unavailable	4 / 3
2026-09-28	Unavailable	Unavailable	4 / 3
2026-09-29	Unavailable	Unavailable	4 / 3
2026-09-30	Unavailable	Unavailable	4 / 3
2026-10-01	Unavailable	Unavailable	4 / 3
2026-10-02	Unavailable	Unavailable	4 / 3
2026-10-03	Unavailable	Unavailable	4 / 3
2026-10-04	Unavailable	Unavailable	4 / 3
2026-10-05	Unavailable	Unavailable	4 / 3
2026-10-06	Unavailable	Unavailable	4 / 3
2026-10-07	Unavailable	Unavailable	4 / 3
2026-10-08	Unavailable	Unavailable	4 / 3
2026-10-09	Unavailable	Unavailable	4 / 3
2026-10-10	Unavailable	Unavailable	4 / 3
2026-10-11	Unavailable	Unavailable	4 / 3
2026-10-12	Unavailable	Unavailable	4 / 3
2026-10-13	Unavailable	Unavailable	4 / 3
2026-10-14	Unavailable	Unavailable	4 / 3
2026-10-15	Unavailable	Unavailable	4 / 3
2026-10-16	Unavailable	Unavailable	4 / 3
2026-10-17	Unavailable	Unavailable	4 / 3
2026-10-18	Unavailable	Unavailable	4 / 3
2026-10-19	Unavailable	Unavailable	4 / 3
2026-10-20	Unavailable	Unavailable	4 / 3
2026-10-21	Unavailable	Unavailable	4 / 2
2026-10-22	Unavailable	Unavailable	4 / 3
2026-10-23	Unavailable	Unavailable	4 / 3
2026-10-24	Unavailable	Unavailable	4 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	5	1
2026-06-01	5	1
2026-07-01	6	1
2026-08-01	6	1
2026-09-01	6	1
2026-10-01	6	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Craig-HallumOct 19

$5.00New observation · no comparable prior

$0$2.75$5.50

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash runway into early 2027Direct metric needs a verified mapping
Achieve clinical milestones for Revita and RejuvaDirect metric needs a verified mapping
Address Nasdaq listing compliancePublished status: Under Pressure

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.6%Typical daily move · historical

Downside history

-96.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Fractyl Health Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative, early-stage healthcare business rather than an established compounder. Its multi-year view depends mainly on advancing Revita and managing cash, while recent performance is below its industry cohort and the thesis state is watch.

What's priced into Fractyl Health Inc

The available valuation model indicates GUTS is expensive versus peers, with a roughly 61% premium, but confidence in that estimate is low. The premium appears tied to Revita's potential, while the evidence does not show that successful submission, commercialization, or cash-burn reduction is already assured.

What the fundamentals likely do

Near term, operating losses and execution risk remain central: recent quarterly operating losses were about $19 million and $21 million, and the announced workforce reduction has not yet shown a full-quarter effect. October's REMAIN-1 results showed 80% of GLP-1-induced weight loss retained at six months versus 67% for sham, but the De Novo submission and commercialization are still planned; the cash-runway extension and lower burn are also plans awaiting proof.

What Fractyl Health Inc hinges on

The multi-year thesis hinges on Revita progressing from clinical results toward FDA submission and commercialization, and on management delivering the planned reduction in cash burn. Near term, a guidance cut or further weakening in jobs data could add pressure, while continued strong results and guidance from healthcare bellwethers could support sector momentum.